Major depression during interferon-alpha treatment: vulnerability and prevention.
Major depression during interferon-alpha treatment: vulnerability and prevention.
复制标题
DOI：
10.31887/dcns.2009.11.4/felotrich
复制
发表时间：
2009
影响因子：
8.3
通讯作者：
Lotrich FE
中科院分区：
文献类型：
--
作者：
Lotrich FE
干扰素治疗期间的严重抑郁障碍(α)可在治疗后几个月内发生，与其他形式的MDD有许多相似之处，大多数患者对干扰素诱导的抑郁症的副作用具有抵抗力，但15%至40%的患者易受影响。一些研究已经使用了抗抑郁药物来预防干扰素-MDD发作的发生，结果表明，预防性抗抑郁药物可能对那些既有阈值下抑郁症状和既往MDD发作史的人特别有用。在非抑郁症患者开始干扰素-α之前的评估中，还涉及到其他几个潜在的干扰素-MDD易感性标志物，包括睡眠质量差、炎性细胞因子病前升高、5-羟色胺系统中的遗传多态、个性和社会支持。这些因素的相互作用强烈地预测了谁有患干扰素-MDD的风险，并表明了个性化预防干扰素-MDD的几个潜在的可修改的靶点，
Major Depressive Disorder (MDD) during interferons (IFN-α) treatment can occur within a few months of therapy, and shares many homologies with other forms of MDD, Most patients are resilient to the side effect ofinterferon-induced depression (IFN-MDD), but 15% to 40% are vulnerable. Several studies have employed antidepressants to prevent the incidence of an IFN-MDD episode, and the results suggest that prophylactic antidepressants may be specifically useful in those with pre-existing subthreshold depressive symptoms andlor a history of prior MDD episodes. Several other potential markers of vulnerability for IFN-MDD have been implicated in assessments of nondepressed patients before they start IFN-α These include poor sleep quality, premorbid elevations in inflammatory cytokines, genetic polymorphisms in the serotonin system, personality, and social support. The interplay of these factors strongly predicts who is at risk for IFN-MDD, and indicates several potentially modifiable targets for the personalized prevention of IFN-MDD,